Literature DB >> 3557197

The outcome of the patients with recurrent cervical carcinoma in terms of lymph node metastasis and treatment.

H T Ng, Y Y Kan, K C Chao, C C Yuan, S K Shyu.   

Abstract

Of the 908 patients who underwent radical hysterectomy and pelvic lymphadenectomy for invasive cervical cancer from 1973 to 1983, 139 (or 15.30%) had recurrences. The recurrent rate in the 175 patients with positive pelvic lymph nodes was 32.6%, compared with a 11.2% in the 733 patients with negative nodes (P less than 0.001). This suggests that cervical cancer patients with negative nodes acquire better prognosis after surgical treatments. Not only is recurrence much less frequent in patients with negative nodes, but also the outcome of treatments is significantly in favor of such patients: (A) 51 recurrent patients refused further treatments owing to personal reasons. None survived over 3 years; (B) The survival rate is far higher for treated patients formerly with negative nodes. Sixty of the 82 patients achieved a 5-year survival of 17.74% compared with a 2-year survival of 21.64% only in 28 patients with positive nodes. This suggests that our treatments on patients with recurrent cervical cancer are more effective when the patients have previously had negative nodes, and that refusal of treatment results in quick death.

Entities:  

Mesh:

Year:  1987        PMID: 3557197     DOI: 10.1016/0090-8258(87)90027-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases.

Authors:  H T Ng; C C Yuan; Y Y Kan; E S Ho; M S Yen; K C Chao
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

2.  The Clinical Aspects and Prognostic Factors Concerning Survival in Patients With Recurrent Cervical Cancer After Radical Hysterectomy and Adjuvant Chemoradiotherapy.

Authors:  Hui-Ting Zhu; Wen-Juan Yan; Yu-Hua Gao
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.